[1]王晓雪,王芝涛,秦 慧.血小板与淋巴细胞比值在多发性骨髓瘤预后中的价值[J].医学信息,2022,35(12):109-112.[doi:10.3969/j.issn.1006-1959.2022.12.026]
　WANG Xiao-xue,WANG Zhi-tao,QIN Hui.Prognostic Value of Platelet to Lymphocyte Ratio in Multiple Myeloma[J].Medical Information,2022,35(12):109-112.[doi:10.3969/j.issn.1006-1959.2022.12.026]
点击复制

血小板与淋巴细胞比值在多发性骨髓瘤预后中的价值()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年12期
页码:
109-112
栏目:
论著
出版日期:
2022-06-15

文章信息/Info

Title:
Prognostic Value of Platelet to Lymphocyte Ratio in Multiple Myeloma
文章编号:
1006-1959（2022）12-0109-04
作者:
王晓雪; 王芝涛; 秦 慧
（1.安徽医科大学第二附属医院血液内科，安徽 合肥 230601；2.安徽医科大学血液病研究中心，安徽 合肥 230032）
Author(s):
WANG Xiao-xue; WANG Zhi-tao; QIN Hui
(1.Department of Hematology,the Second Hospital of Anhui Medical University,Hefei 230601,Anhui,China; 2.Hematology Research Center of Anhui Medical University,Hefei 230032,Anhui,China)
关键词:
多发性骨髓瘤; 血小板与淋巴细胞比值; 总体生存期
Keywords:
Multiple myeloma; Platelet to lymphocyte ratio; Overall survival
分类号:
R733.3
DOI:
10.3969/j.issn.1006-1959.2022.12.026
文献标志码:
A
摘要:
目的 分析外周血血小板计数与淋巴细胞比值（PLR）在多发性骨髓瘤患者预后中的价值。方法 收集2015年1月-2019年9月安徽医科大学第二附属医院收治的138例初诊多发性骨髓瘤患者的临床资料，依据受试者工作特征（ROC）曲线确定PLR的最佳截断值并将患者分为高PLR组和低PLR组，比较两组一般资料及实验室指标，并分析PLR在预后中的价值。结果 ROC曲线分析显示，RLR预测多发性骨髓瘤生存最佳截断值为133.88，其中AUC为0.600，灵敏度46.60%，特异度76.60%。高PLR组和低PLR组分型、有无髓外疾病比较，差异有统计学意义（P＜0.05）。138例多发性骨髓瘤患者共58例死亡，死亡率为42.03%；高PLR组中位OS为29个月（1~71个月），低PLR组中位OS为27个月（1~79个月），组间比较，差异有统计学意义（P＜0.05）；单因素Cox分析显示，EOCG评分、血小板计数、PLR水平、乳酸脱氢酶、髓外病变与多发性骨髓瘤患者OS有关；多因素Cox分析显示，血小板计数＜100×109/L、PLR≥133.88、乳酸脱氢酶≥250 U/L、髓外病变是影响多发性骨髓瘤患者OS的独立不良预后因素。结论 初诊时外周血PLR与多发性骨髓瘤髓外病变相关，对预后具有一定的预测价值，是多发性骨髓瘤患者OS的独立预后预测指标。
Abstract:
Objective To analyze the prognostic value of peripheral blood platelet to lymphocyte ratio (PLR) in patients with multiple myeloma.Methods The clinical data of 138 patients with newly diagnosed multiple myeloma admitted to the Second Affiliated Hospital of Anhui Medical University from January 2015 to September 2019 were collected. The optimal cut-off value of PLR was determined according to the receiver operating characteristic (ROC) curve and the patients were divided into high PLR group and low PLR group. The general data and laboratory indexes were compared between the two groups, and the value of PLR in prognosis was analyzed.Results ROC curve analysis showed that the optimal cutoff value of RLR for predicting the survival of multiple myeloma was 133.88, with AUC of 0.600, the sensitivity was 46.60% and specificity was 76.60%. There was a statistically significant difference between the high PLR group and the low PLR group in component types and the presence of extramyelopathy (P<0.05). There were 58 deaths in 138 patients with multiple myeloma, with a mortality rate of 42.03%; the median OS in the high PLR group was 29 months (1-71 months), and that in the low PLR group was 27 months (1-79 months), the difference between groups was statistically significant (P<0.05). Univariate Cox analysis showed that EOCG score, platelet count, PLR level, lactate dehydrogenase and extramedullary lesions were associated with OS in patients with multiple myeloma. Multivariate Cox analysis showed that platelet count <100×109/L, PLR≥133.88, lactate dehydrogenase≥250 U/L and extramedullary lesions were independent poor prognostic factors for OS in patients with multiple myeloma.Conclusion PLR in peripheral blood at initial diagnosis is associated with extramedullary lesions in multiple myeloma, which has certain predicative value for prognosis and is an independent prognostic predictor of OS in patients with multiple myeloma.

参考文献/References:

[1]Soliman AM,Das S,Teoh SL.Next-Generation Biomarkers in Multiple Myeloma: Understanding the Molecular Basis for Potential Use in Diagnosis and Prognosis[J].Int J Mol Sci,2021,22(14):7470.[2]Kumar SK,Callander NS,Alsina M,et al.NCCN Guidelines Insights:Multiple Myeloma,Version 3.2018[J].J Natl Compr Canc Netw,2018,16(1):11-20.[3]Avet-Loiseau H.Introduction to a review series on advances in multiple myeloma[J].Blood,2019,133(7):621.[4]Rodriguez-Otero P,Paiva B,San-Miguel JF.Roadmap to cure multiple myeloma[J].Cancer Treatment Reviews,2021,100:102284.[5]Podar K,Chauhan D,Anderson KC.Bone marrow microenvironment and the identification of new targets for myeloma therapy[J].Leukemia,2009,23(1):10-24.[6]Ceran MU,Tasdemir U,Colak E,et al.Can complete blood count inflammatory parameters in epithelial ovarian cancer contribute to prognosis? - a survival analysis[J].J Ovarian Res,2019,12(1):16.[7]Lochowski M,Chalubińska-Fendler J,Zawadzka I,et al.The Prognostic Significance of Preoperative Platelet-to-Lymphocyte and Neutrophil-to-Lymphocyte Ratios in Patients Operated for Non-Small Cell Lung Cancer[J].Cancer management and research,2021,13:7795-7802.[8]中国医师协会血液科医师分会，中华医学会血液学分会，中国多发性骨髓瘤工作组.中国多发性骨髓瘤诊治指南(2013年修订)[J].中华内科杂志,2013,52(9):791-795.[9]Szudy-Szczyrek A,Mlak R,Mielnik M,et al.Prognostic value of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in multiple myeloma patients treated with thalidomide-based regimen[J].Ann Hematol,2020,99(12):2881-2891.[10]Munshi NC,Avet-Loiseau H,Rawstron AC,et al.Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma[J].JAMA Oncology,2017,3(1):28.[11]Sweiss K,Lee J,Mahmud N,et al.Combined immune score of lymphocyte to monocyte ratio and immunoglobulin levels predicts treatment-free survival of multiple myeloma patients after autologous stem cell transplant[J].Bone Marrow Transplant,2020,55(1):199-206.[12]Kaynar M,Yildirim ME,Gul M,et al.Benign prostatic hyperplasia and prostate cancer differentiation via platelet to lymphocyte ratio[J].Cancer Biomarkers,2015,15(3):317-323.[13]Schobert IT,Savic LJ,Chapiro J,et al.Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE[J].European Radiology,2020,30(10):5663-5673.[14]Russo A,Russano M,Franchina T,et al.Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR),and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC):A Large Retrospective Multicenter Study[J].Adv Ther,2020,37(3):1145-1155.[15]Fang T,Wang Y,Yin X,et al.Diagnostic Sensitivity of NLR and PLR in Early Diagnosis of Gastric Cancer[J].Journal of Immunology Research,2020,2020:1-9.[16]Peterson JE,Zurakowski D,Italiano JE,et al.Normal ranges of angiogenesis regulatory proteins in human platelets[J].American Journal of Hematology,2010,85(7):487-493.[17]Kyle RA,Gertz MA,Witzig TE,et al.Review of 1027 patients with newly diagnosed multiple myeloma[J].Mayo Clin Proc,2003;78(1):21-33.[18]Tao ZF,Fu WJ,Yuan ZG.et al.Prognostic factors and staging systems of multiple myeloma[J].Chin Med J (Engl)2007,120(19):1655-1658.[19]赵泽昊,孙海英.初诊多发性骨髓瘤患者血液炎症指标与预后的相关性分析[J].现代肿瘤医学,2019,27(21):3878-3881.[20]崔壮壮,张媛媛,金北平,等.中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值对初诊多发性骨髓瘤患者总生存和无进展生存的预测意义[J].解放军医学院学报,2019,40(2):121-126.[21]Li Y,Li H,Li W,et al.Pretreatment neutrophil/lymphocyte ratio but not platelet/lymphocyte ratio has a prognostic impact in multiple myeloma[J].Journal of Clinical Laboratory Analysis,2017,31(5):e22107.

相似文献/References:

[1]贾海英,黄睿,王玲玲,等.多发性骨髓瘤患者淋巴细胞亚群变化对免疫功能的影响研究[J].医学信息,2018,31(01):147.[doi:10.3969/j.issn.1006-1959.2018.01.057]
　JIA Hai-ying,HUANG Rui,WANG Ling-ling,et al.The Effect of Lymphocyte Subgroup Changes on Immune Function in Patients with Multiple Myeloma[J].Medical Information,2018,31(12):147.[doi:10.3969/j.issn.1006-1959.2018.01.057]
[2]黄珍艳.实验室指标对多发性骨髓瘤的诊断价值分析[J].医学信息,2018,31(05):155.[doi:10.3969/j.issn.1006-1959.2018.05.056]
　HUANG Zhen-yan.Diagnostic Value of Laboratory Markers for Multiple Myeloma[J].Medical Information,2018,31(12):155.[doi:10.3969/j.issn.1006-1959.2018.05.056]
[3]冯江芳.多发性骨髓瘤患者校正血钙的临床分析[J].医学信息,2018,31(10):87.[doi:10.3969/j.issn.1006-1959.2018.10.026]
　FENG Jiang-fang.Clinical Analysis of Corrected Serum Calcium in Patients with Multiple Myeloma[J].Medical Information,2018,31(12):87.[doi:10.3969/j.issn.1006-1959.2018.10.026]
[4]王 然,孙言非.血清免疫固定电泳、血清蛋白电泳及免疫球蛋白定量对 多发性骨髓瘤的临床诊断价值[J].医学信息,2019,32(11):173.[doi:10.3969/j.issn.1006-1959.2019.11.054]
　WANG Ran,SUN Yan-fei.Clinical Diagnostic Value of Serum Immunofixation Electrophoresis,Serum Protein Electrophoresis and Immunoglobulin Quantification for Multiple Myeloma[J].Medical Information,2019,32(12):173.[doi:10.3969/j.issn.1006-1959.2019.11.054]
[5]金 英.硼替佐米治疗老年多发性骨髓瘤的效果[J].医学信息,2020,33(06):146.[doi:10.3969/j.issn.1006-1959.2020.06.047]
　JIN Ying.Effect of Bortezomib in the Treatment of Elderly Multiple Myeloma[J].Medical Information,2020,33(12):146.[doi:10.3969/j.issn.1006-1959.2020.06.047]
[6]郑 新,张 颖.慢阻肺患者PSQI评分与NLR、PLR、CRP水平及急性加重频率的相关性[J].医学信息,2020,33(12):103.[doi:10.3969/j.issn.1006-1959.2020.12.031]
　ZHENG Xin,ZHANG Ying.Correlation of PSQI Score with NLR,PLR,CRP Level and Frequency of Acute Exacerbation in COPD Patients[J].Medical Information,2020,33(12):103.[doi:10.3969/j.issn.1006-1959.2020.12.031]
[7]侯婷婷,刘尚全.PLR与2型糖尿病合并颈动脉粥样斑块患者的相关性[J].医学信息,2021,34(04):103.[doi:10.3969/j.issn.1006-1959.2021.04.027]
　HOU Ting-ting,LIU Shang-quan.The Correlation Between PLR and Type 2 Diabetes Mellitus with Carotid Atherosclerotic Plaque[J].Medical Information,2021,34(12):103.[doi:10.3969/j.issn.1006-1959.2021.04.027]
[8]覃泽东,夏玉梅,陈 莉,等.多发性骨髓瘤合并颅内浆细胞瘤的临床及影像学特点分析[J].医学信息,2021,34(05):111.[doi:10.3969/j.issn.1006-1959.2021.05.031]
　QIN Ze-dong,XIA Yu-mei,CHEN Li,et al.Analysis of Clinical and Imaging Characteristics of Multiple Myeloma Combined with Intracranial Plasmacytoma[J].Medical Information,2021,34(12):111.[doi:10.3969/j.issn.1006-1959.2021.05.031]
[9]晏建国,罗 萍,胡 飞,等.多发性骨髓瘤患者EB病毒检测及其临床意义[J].医学信息,2021,34(15):86.[doi:10.3969/j.issn.1006-1959.2021.15.022]
　YAN Jian-guo,LUO Ping,HU Fei,et al.Detection of Epstein-Barr Virus in Patients with Multiple Myeloma and Its Clinical Significance[J].Medical Information,2021,34(12):86.[doi:10.3969/j.issn.1006-1959.2021.15.022]
[10]李 玲.β2-微球蛋白、C反应蛋白及乳酸脱氢酶检测在多发性骨髓瘤诊治中的价值[J].医学信息,2021,34(16):187.[doi:10.3969/j.issn.1006-1959.2021.16.054]
　LI Ling.The Value of β2-microglobulin,C-reactive Protein and Lactate Dehydrogenase in the Diagnosis and Treatment of Multiple Myeloma[J].Medical Information,2021,34(12):187.[doi:10.3969/j.issn.1006-1959.2021.16.054]

更新日期/Last Update: 1900-01-01